Medical education · Dr. Benedikt Dubois

22 Apr 2026 · Phone · Dr. Benedikt Dubois, LMU Klinikum München · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0034—

Capture insight from this engagement

Location: LMU Klinikum München
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround
Elderly / ECOG 2 patients
Brain-metastasis subgroup data

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

How should grade 2 infusion reactions be managed without steroids?
What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?

Notes

Medical education with thoracic medical oncologist at LMU Klinikum München. Discussed pd-l1 testing turnaround, elderly / ecog 2 patients, brain-metastasis subgroup data.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 5
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0034

Audit history (0)

All create, update and approval events for this record

No audit events in sample data